今天是:2019-03-26 星期二

探究冠心病患者血中长链非编码RNA水平与冠脉钙化之间的联系
下载XML文档

注册号:

Registration number:

ChiCTR1900021911 

最近更新日期:

Date of Last Refreshed on:

2019-03-15 

注册时间:

Date of Registration:

2019-03-15 

注册号状态:

预注册  

Registration Status:

Prospective registration  

注册题目:

探究冠心病患者血中长链非编码RNA水平与冠脉钙化之间的联系 

Public title:

To explore the association between circulating long non-coding RNA levels and coronary artery calcification in patients with coronary heart disease 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

探究冠心病患者血中长链非编码RNA水平与冠脉钙化之间的联系 

Scientific title:

To explore the association between circulating long non-coding RNA levels and coronary artery calcification in patients with coronary heart disease 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

娄亚柯 

研究负责人:

刘巍 

Applicant:

Lou Yake 

Study leader:

Liu Wei 

申请注册联系人电话:

Applicant telephone:

+86 13370718351 

研究负责人电话:

Study leader's telephone:

+86 18910938225 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

2533855091@qq.com 

研究负责人电子邮件:

Study leader's E-mail:

liuwei@ccmu.edu.cn 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

北京市朝阳区安贞路2号 

研究负责人通讯地址:

北京市朝阳区安贞路2号 

Applicant address:

2 Anzhen Road, Chaoyang District, Beijing 

Study leader's address:

2 Anzhen Road, Chaoyang District, Beijing 

申请注册联系人邮政编码:

Applicant postcode:

 

研究负责人邮政编码:

Study leader's postcode:

 

申请人所在单位:

首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所 

Applicant's institution:

Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease , Beijing , China 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

2018052X 

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京安贞医院伦理委员会 

Name of the ethic committee:

Ethics Committee of Beijing Anzhen Hospital, Capital Medical University 

伦理委员会批准日期:

Date of approved by ethic committee:

2019-01-03 

伦理委员会联系人:

吴朝阳 

Contact Name of the ethic committee:

Wu Chaoyang 

伦理委员会联系地址:

安贞医院综合病房楼B座3032 

Contact Address of the ethic committee:

Room 3032, Block B, Comprehensive Ward Building, Anzhen Hospital, 2 Anzhen Road, Chaoyang District, Beijing 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所 

Primary sponsor:

Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease 

研究实施负责(组长)单位地址:

北京市朝阳区安贞路2号首都医科大学附属北京安贞医院 

Primary sponsor's address:

2 Anzhen Road, Chaoyang District, Beijing 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所

具体地址:

北京市朝阳区安贞路2号

Institution
hospital:

Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease

Address:

2 Anzhen Road, Chaoyang District

经费或物资来源:

国家自然科学基金 

Source(s) of funding:

National Natural Science Foundation of China Project  

研究疾病:

冠心病 

Target disease:

Coronary Heart Disease 

研究疾病代码:

 

Target disease code:

 

研究类型:

基础科学研究 

Study type:

Basic Science 

研究所处阶段:

探索性研究/预试验 

Study phase:

研究目的:

本研究的目的是探讨血中长链非编码RNA(lncRNA)水平与冠心病患者冠状动脉钙化的关系,并验证所选择的lncRNA是否能够反映这些患者的阻塞性冠状动脉疾病。 

Objectives of Study:

The purpose of this study is to explore the association between circulating long non-coding RNA (lncRNA) levels and coronary artery calcification in patients with coronary heart disease, and testify whether the selected lncRNAs could reflect the obstructive coronary artery disease in these patients. 

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

研究设计:

析因 

Study design:

Factorial 

纳入标准:

本研究纳入年龄在45-70岁之间,冠心病发生概率中等的患者。 

Inclusion criteria

Patients aged 45 to 70 years with moderate probability of coronary artery disease are included in the study. 

排除标准:

已知慢性肾功能衰竭、胰岛素依赖型糖尿病、既往AMI史、经皮冠状动脉介入治疗或冠状动脉搭桥术、或有退行性主动脉瓣疾病或急性冠状动脉综合征的患者不纳入研究。 

Exclusion criteria:

Patients with known chronic renal failure, insulin dependent DM, previous history of AMI, percutaneous coronary artery intervention or coronary artery bypass graft, or with degenerative aortic valve disease or acute coronary syndrome are excluded from the study. 

研究实施时间:

Study execute time:

From2019-04-01To 2019-12-01 

干预措施:

Interventions:

组别:

根据lncRNA差异性表达分组

样本量:

400

Group:

Grouping according to differential expression of lncRNA

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国 

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City: